Common Drugs Show Little Effect on Long COVID Fatigue

Commonly prescribed medications demonstrated marginal and short-term efficacy in treating severe fatigue associated with long COVID, according to an open-label randomized trial published this week. The study investigated the impact of an anti-inflammatory pill and a combination of a heartburn drug with an antihistamine, comparing their effects against usual care for patients experiencing debilitating fatigue.

Researchers found that while both treatment regimens showed a slight improvement in fatigue scores over a 4-week period, the benefits were not substantial enough to be considered clinically significant for many participants. The anti-inflammatory drug, specifically an interleukin-1 receptor antagonist, provided a modest reduction in fatigue, but the effect diminished significantly after the initial treatment phase. Similarly, the combination of famotidine (a heartburn medication) and cetirizine (an antihistamine) yielded a small, temporary improvement in fatigue levels.

The trial, which enrolled 120 participants suffering from persistent fatigue for at least 6 months post-COVID-19 infection, aimed to identify accessible and widely available treatments. The study's findings suggest that these commonly used drugs are unlikely to be a primary solution for the complex and often multi-faceted symptoms of long COVID fatigue. The researchers emphasized the need for further investigation into more targeted and potentially novel therapeutic approaches.

This study highlights the ongoing challenges in managing long COVID, a condition that continues to affect millions globally. The limited success of these conventional medications underscores the complexity of the underlying biological mechanisms driving long COVID symptoms. Future research will likely focus on understanding the specific inflammatory pathways and neurological impacts contributing to prolonged fatigue and exploring treatments that address these root causes more directly.